Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) (“Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today the pricing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE